The 41 references in paper D. Goryachev V., M. Telnykh Yu, Д. Горячев В., М. Тельных Ю. (2018) “Планирование регистрационной программы исследований препаратов базисной противовоспалительной терапии ревматоидного артрита // Planning of a Clinical Data Registry for Basic Anti-Inflammatory Drugs for the Treatment of Rheumatoid Arthritis” / spz:neicon:vedomostincesmp:y:2018:i:4:p:238-245

1
Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, ред. Ревматология. Национальное руководство. М.: ГЭОТАР-Медиа; 2008. [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova VA. Rheumatology. National guidance. Moscow: GEOTARMedia; 2008 (In Russ.)]
(check this in PDF content)
2
Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(1):34–45. https://doi.org/10.1136/ ard.2005.044354
(check this in PDF content)
3
Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of international task force. Ann Rheum Dis. 2010;69(4):631–7. https:// doi.org/10.1136/ard.2009.123919
(check this in PDF content)
4
Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with diseasemodifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50(7):2072–81. https://doi. org/10.1002/art.20351
(check this in PDF content)
5
Насонов ЕЛ, ред. Ревматология. Клинические рекомендации. М.: ГЭОТАР-Медиа; 2010. [Nasonov EL, ed. Rheumatology. Clinical guidelines. Moscow: GEOTAR-Media; 2010 (In Russ.)]
(check this in PDF content)
6
Горячев ДВ, Тельных МЮ, Бунятян НД. Регуляторные подходы к оценке биоаналогов для лечения ревматических заболеваний. Ведомости Научного Центра экспертизы средств медицинского применения. 2017;7(3):155–63. [Goryachev DV, Telnykh MYu, Bunyatyan ND. Regulatory approaches to evaluation of biosimilars for treatment of rheumatic diseases. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2017;7(3):155–63 (In Russ.)]. https:// doi.org/10.30895/1991-29192017-7-3-155-163
(check this in PDF content)
7
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. https:// doi.org/10.1002/art.27584
(check this in PDF content)
8
Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009;60(8):2262–71. https:// doi.org/10.1002/art.24661
(check this in PDF content)
9
Aletaha D, Funovits J, Ward MM, Smolen JS, Kvien TK. Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline. Arthritis Rheum. 2009;61(3):313–20. https:// doi.org/10.1002/art.24282
(check this in PDF content)
10
Wit MP, Smolen JS, Gossec L, van der Heijde D. Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann Rheum Dis. 2011;70:891–5. https://doi. org/10.1136/ard.2010.146662
(check this in PDF content)
11
Boers M. International consensus on which measures to use in rheumatoid arthritis clinical trials. Neth J Med 1993;43(1–2):55–8. PMID: 7694164
(check this in PDF content)
12
Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol. 1999;26(3):705– 11. PMID: 10090187
(check this in PDF content)
13
Fautrel B, Guillemin F, Meyer O, de Bandt M, Berthelot JM, Flipo RM, et al. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists’ preferences. Arthritis Rheum. 2009;61(4):425–34. https://doi.org/10.1002/ art.24588
(check this in PDF content)
14
Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Martin Mola E, Pedersen R, et al. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann Rheum Dis. 2009;68(7):1113–8. https:// doi.org/10.1136/ard.2008.094375
(check this in PDF content)
15
Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67(10):1360–4. https://doi.org/10.1136/ ard.2008.091454
(check this in PDF content)
16
Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis. 2007;66(Suppl. 3):iii56-iii60. https://doi.org/10.1136/ ard.2007.078360
(check this in PDF content)
17
Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum. 2002;46(4):913–20. PMID: 11953967
(check this in PDF content)
18
Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005; 23(5 Suppl. 39):S100–8. PMID: 16273793
(check this in PDF content)
19
Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology / European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573–86. https:// doi.org/10.1002/art.30129
(check this in PDF content)
20
Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52(9):2625–36. https:// doi.org/10.1002/art.21235
(check this in PDF content)
21
Heiberg T, Kvien TK, Mowinckel P, Aletaha D, Smolen JS, Hagen KB. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(7):967–71. https://doi.org/10.1136/ ard.2007.077503
(check this in PDF content)
22
Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244–57. PMID: 12595618
(check this in PDF content)
23
Smolen JS, Aletaha D. Activity assessments in rheumatoid arthritis. Curr Opin Rheumatol. 2008;20(3):306–13. https://doi.org/10.1097/ BOR.0b013e3282fbd382
(check this in PDF content)
24
Soubrier M, Dougados M. Selecting criteria for monitoring patients with rheumatoid arthritis. Joint Bone Spine. 2005;72(2):129–34. https:// doi.org/10.1016/j.jbspin.2004.05.007
(check this in PDF content)
25
Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum. 2006;54(9):2784–92. https:// doi.org/10.1002/art.22052
(check this in PDF content)
26
Bruynesteyn K, van der Heijde D, Boers M, Lassere M, Boonen A, Edmonds J, et al. Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. J Rheumatol. 2001;28(4):904–10. PMID: 11327274
(check this in PDF content)
27
Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford). 2007;46(2):342–9. https:// doi.org/10.1093/rheumatology/kel237
(check this in PDF content)
28
Helm-van Mil AH, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum. 2008;58(8):2241–7. https:// doi.org/10.1002/art.23681
(check this in PDF content)
29
Gulfe A, Aletaha D, Saxne T, Geborek P. Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents. BMC Musculoskelet Disord. 2009;10:41. https:// doi.org/10.1186/1471-2474-10-41
(check this in PDF content)
30
Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis. 2010;69(6):1058– 64. https:// doi.org/10.1136/ard.2009.114652
(check this in PDF content)
31
Schoels M, Kapral T, Stamm T, Smolen JS, Aletaha D. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study. Ann Rheum Dis. 2007;66(8):1059– 65. https:// doi.org/10.1136/ard.2006.061820
(check this in PDF content)
32
Boers M. Combination treatment in autoimmune diseases. Methodology of combination trials. Springer Semin Immunopathol. 2001;23(1–2):27–33. PMID: 11455857
(check this in PDF content)
33
Kapral T, Dernoschnig F, Machold KP, Stamm T, Schoels M, Smolen JS, et al. Remission by composite scores in rheumatoid arthritis: are ankles and feet important? Arthritis Res Ther. 2007;9(4):R72. https:// doi.org/10.1186/ar2270
(check this in PDF content)
34
Boers M, Anderson JJ, Felson DT. Deriving an operational definition of low disease activity state in rheumatoid arthritis. J Rheumatol. 2003;30(5):1112–4. PMID: 12734919
(check this in PDF content)
35
Suresh E, Lambert CM. Combination treatment strategies in early rheumatoid arthritis. Ann Rheum Dis. 2005;64(9):1252–6. https:// doi.org/10.1136/ard.2004.032219
(check this in PDF content)
36
Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84. https:// doi.org/10.1002/art.23721
(check this in PDF content)
37
Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford). 2002;41(8):892–8. PMID: 12154206
(check this in PDF content)
38
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8. https:// doi.org/10.1136/ard.2010.138461
(check this in PDF content)
39
Garnero P, Landewe R, Boers M, Verhoeven A, van der Linden S, Christgau S, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum. 2002;46(11):2847–56. https://doi.org/10.1002/ art.10616
(check this in PDF content)
40
Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. 2005;52(1):36–41. https://doi.org/10.1002/ art.20716
(check this in PDF content)
41
Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum. 2007;57(6):935–42. https://doi. org/10.1002/art.22895 Статья поступила 14.06.2018
(check this in PDF content)